ConvaTec Group PLC (CTEC) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally.
Total Assets Chart for ConvaTec Group PLC
ConvaTec Group PLC (CTEC) total assets for FY2025 were GBP 3.8B, a 7.6% change from FY2024. ConvaTec Group PLC's total assets grew from GBP 4.7B in 2009 to GBP 3.8B in 2025 (-20.0% over 16 years). Total assets compound annual growth rate: 5-year CAGR of 0.1%, 10-year CAGR of -0.0%.
Total Assets (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £4.48B
- Implied Share Price
- £2.30
- Enterprise Value
- £5.79B
- Revenue (TTM)
- £2.49B
- EBITDA
- £582.00M
- Profit Margin
- 4.98%
- Trailing P/E
- 45.92
- Forward P/E
- 15.75
- Price/Book (MRQ)
- 4.30
- Price/Sales (TTM)
- 1.80
- EV/EBITDA
- 17.25
- EV/Revenue
- 3.13
- Dividend Yield
- 3.24%
- Book Value
- £0.54
- Free Cash Flow (FY2025)
- £342.03M
- Free Cash Flow Yield
- 7.64%
Snapshot as of 15th August 2026 — not point-in-time controlled, may lag the live market by a few days.